Intramuscular Injections of Testosterone Undecanoate Restores and Maintains Testosterone Levels in Hypogonadal Men: Presented at AUA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Intramuscular Injections of Testosterone Undecanoate Restores and Maintains Testosterone Levels in Hypogonadal Men: Presented at AUA

By Deborah Brauser

ORLANDO, Fla -- May 27, 2008 -- Intramuscular injections of long-acting testosterone undecanoate appear to restore and maintain normal testosterone levels in a significantly high number of phase 3 study patients suffering from hypogonadism, according to research presented here at the American Urological Association (AUA) Annual Meeting.

Abraham Morgentaler, MD, Associate Clinical Professor of Urology, Harvard Medical School, Boston, Massachusetts, reported the results in a late-breaking news presentation on May 20.

This phase 3, multicentre, open-label, randomised trial was designed to assess the safety, efficacy, and pharmacokinetics of testosterone undecanoate intramuscular injections. In the study, men with hypogonadism and low serum testosterone levels were treated with 3 intramuscular injections of testosterone undecanoate every 10 weeks.

"This form of testosterone treatment would require only 5 injections per year," said Dr. Morgentaler, "[making it] an appealing alternative for many men who may object to existing testosterone treatments such as twice-monthly injections or daily skin applications."

In the trial, 130 men aged at least 18 years who had serum testosterone levels <300 ng/dL received intramuscular testosterone undecanoate at a dose of 750 mg at baseline, at week 4, and at week 14. They were followed for an additional 10 weeks.

At the end of the study, 94% of patients reached and maintained normal serum testosterone levels.

Adverse events reported by patients included acne (4.6%), fatigue (3.1%), and injection site pain (3.1%).

"If approved, this may be very good for treating men with hypogonadism. No treatment is perfect. Pills often lead to concerns about liver problems and while 75% of patients use gels, most don't like it. A long-lasting injection means longer-lasting help," said Dr. Morgentaler.

[Presentation title: Safety, Efficacy, and Pharmacokinetics of Testosterone Undecanoate Long-Acting Injection of Hypogonadism: Results of a Phase III Clinical Trial.]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities